Side Effects and Its Management in Adjuvant Endocrine Therapy for Breast Cancer: A Matter of Communication and Counseling

被引:5
|
作者
Johnsson, Aina [1 ,2 ,8 ]
Fugl-Meyer, Kerstin [2 ,3 ]
Bordas, Pal [4 ,5 ]
ahman, Janet [4 ]
Von Wachenfeldt, Anna [6 ,7 ]
机构
[1] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[2] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Huddinge, Sweden
[3] Karolinska Univ Hosp, Dept Funct Area Social Work Healthcare, Stockholm, Sweden
[4] Sunderby Hosp, Dept Radiol, Norrbotten Mammog Screening Program, Lulea, Sweden
[5] Umea Univ, Dept Radiat Sci, Oncol, Umea, Sweden
[6] Soder Sjukhuset, Dept Oncol, Stockholm, Sweden
[7] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden
[8] Karolinska Inst, Dept Oncol Pathol, S-17177 Stockholm, Sweden
关键词
Breast cancer; anti-hormonal side effects; sexuality; professional support; focus groups; PRACTICE GUIDELINE UPDATE; CLINICAL-PRACTICE; HORMONAL-THERAPY; AMERICAN SOCIETY; AROMATASE INHIBITORS; WOMEN; DISCONTINUATION; TAMOXIFEN; METAANALYSIS; PREDICTORS;
D O I
10.1177/11782234221145440
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective:Women with a newly diagnosed hormone receptor-positive breast cancer are offered adjuvant endocrine therapy (AET). Although the treatment reduces the risk of relapse and death not all women are adherent to it. Many factors, including the therapy's menopausal side effects, can adversely affect adherence to the treatment. This study explores the extent to which women treated with AET perceived that health care providers addressed their side effects. Methods:Ten focus groups were set up, containing between four to nine women. In total, 58 women participated in the study-45 from the Stockholm metropolitan region and 13 from the scarcely populated Norrbotten region. The interviews were analyzed using qualitative content analysis with an inductive approach. Results:The women were usually satisfied with the care they received from the health care providers. However, their experiences were more complex when it came to their satisfaction with the care in terms of the menopausal side effects of therapy, sexuality in particular. The participants reported that their healthcare providers rarely asked about sex life-related side effects of the treatment. Conclusions:Health care providers need to communicate and consult about issues related to their patients' sex lives following their breast cancer diagnosis and during their treatment.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Adjuvant Endocrine Therapy for Premenopausal Breast Cancer REPLY
    Francis, Prudence A.
    Pagani, Olivia
    Regan, Meredith M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (17): : 1684 - 1685
  • [42] Male Breast Cancer and Adherence to Adjuvant Endocrine Therapy
    Lee, Inyoung
    Lee, Wan-Ju
    Calip, Gregory S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 189 - 190
  • [43] ADJUVANT ENDOCRINE THERAPY REGIMENS IN BREAST-CANCER
    JAKESZ, R
    HAUSMANINGER, H
    WIENER KLINISCHE WOCHENSCHRIFT, 1984, 96 (13) : 492 - 499
  • [44] Adjuvant endocrine therapy in premenopausal women with breast cancer
    Antonio González Martín
    Susana de la Cruz
    Raúl Márquez
    Breast Cancer Research and Treatment, 2010, 123 : 43 - 47
  • [45] Evolution of endocrine adjuvant therapy for early breast cancer
    Lonning, Per Eystein
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 : S19 - S30
  • [46] Adjuvant endocrine therapy for premenopausal women with breast cancer
    Puhalla, Shannon
    Brufsky, Adam
    Davidson, Nancy
    BREAST, 2009, 18 : S122 - S130
  • [47] Adjuvant Endocrine Therapy and Bone Health in Breast Cancer
    Gregory A. Clines
    Palak Choksi
    Catherine Van Poznak
    Current Osteoporosis Reports, 2015, 13 : 263 - 273
  • [48] Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer
    Mundhenke, Christoph
    Schem, Christian
    Jonat, Walter
    BREAST CARE, 2008, 3 (05) : 317 - 324
  • [49] Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
    Francis, P. A.
    Pagani, O.
    Fleming, G. F.
    Walley, B. A.
    Colleoni, M.
    Lang, I.
    Gomez, H. L.
    Tondini, C.
    Ciruelos, E.
    Burstein, H. J.
    Bonnefoi, H. R.
    Bellet, M.
    Martino, S.
    Geyer, C. E., Jr.
    Goetz, M. P.
    Stearns, V.
    Pinotti, G.
    Puglisi, F.
    Spazzapan, S.
    Climent, M. A.
    Pavesi, L.
    Ruhstaller, T.
    Davidson, N. E.
    Coleman, R.
    Debled, M.
    Buchholz, S.
    Ingle, J. N.
    Winer, E. P.
    Maibach, R.
    Rabaglio-Poretti, M.
    Ruepp, B.
    Di Leo, A.
    Coates, A. S.
    Gelber, R. D.
    Goldhirsch, A.
    Regan, M. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (02): : 122 - 137
  • [50] Adjuvant endocrine Therapy in early stage Breast Cancer
    Ruckhaberle, Eugen
    Salmen, Jessica
    Fehm, Tanja
    GYNAKOLOGE, 2018, 51 (11): : 972 - 979